Last Transcript: Metsera, Inc.

Date Insider Type Main position Quantity % Market Cap.
11/13/25
Fidelity Management & Research Co. LLC
OthersCompany 2,230,450 2.1183%
11/13/25 Issuer sale

Chief Financial Officer

788,314 0.7487%
11/13/25
Population Health Partners LLC
Issuer saleCompany 12,767,462 12.1257%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-15.24% - - 7.43B
+2.35%+2.74%+38.10%+74.02% 56.54B
-0.21%-7.38%+27.52%+63.59% 53.6B
-2.44%+1.40%-15.61%-13.72% 22.91B
-2.85%-7.78%-9.28%+352.92% 21.37B
+2.49%-0.92%+23.57%-11.65% 20.27B
+0.79%-1.06%+33.99%-30.63% 17.56B
+0.58%-5.88%+19.40%+572.88% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
-5.25%-4.23%+42.32%+160.72% 13.33B
Average -0.15%-3.79%+35.87%+161.77% 25.98B
Weighted average by Cap. +0.21%-2.96%+30.79%+122.01%
Logo Metsera, Inc.
Metsera Inc is a United States-based biopharmaceutical company. The Company is engaged in developing medicines and solutions for obesity and metabolic diseases. It offers a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with profiles to address multiple therapeutic targets and meet the future needs of a weight loss treatment landscape. Its solutions helps to reduce the physical, emotional, and economic burdens of obesity as a driver of diseases. In addition it offers HALO, which is a peptide lipidation platform technology, which enables peptides to bind simultaneously to albumin and to a drug target.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. MTSR Stock